all report title image
  • Published In : Apr 2024
  • Code : CMI4886
  • Pages : 165
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

The global canine atopic dermatitis treatment drugs market is estimated to be valued at USD 1,494.4 Mn in 2024 and is expected to exhibit a CAGR of 10.7% during the forecast period (2024-2031). Canine atopic dermatitis is a chronic skin condition observed in domestic dogs. It is characterized by inflammation and infections of the skin. The prevalence of atopic dermatitis has been increasing among pet dogs over the past few decades. The exact causes are unknown, but it is believed to involve genetic and environmental factors that cause the immune system to overreact to substances that are normally harmless. Dogs with atopic dermatitis experience severe itching, inflammation, and skin lesions that lead to discomfort. Antihistamines and corticosteroids have traditionally been used to manage the symptoms. However, they do not cure the condition and long-term use can cause side effects. Therefore, there is a need for safe and effective treatment drugs that can relieve symptoms and modify the disease. Several pharmaceutical companies are investing in research and developing targeted biologics, immunomodulators, and other novel treatment approaches.

Market Dynamics:

The global canine atopic dermatitis treatment drugs market is driven by factors such as rising pet ownership, rising research and development activities, and increasing prevalence of canine atopic dermatitis, and new product launches. The market has witnessed the approval and launch of several new drugs in recent years which has expanded the treatment options available. However, high treatment costs associated with novel drugs is a restraint. The market players have opportunities for growth in untapped emerging markets and further development of advanced therapeutics.

Key Features of the Study:

  • This report provides an in-depth analysis of the global canine atopic dermatitis treatment drugs market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global canine atopic dermatitis treatment drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies. 
  • Key companies covered as a part of this study include Bioiberica S.A.U, Dechra Pharmaceuticals PLC, Elanco, NIPPON ZENYAKU KOGYO CO., LTD, Vimian, TORAY INDUSTRIES, INC., Zoetis, Virbac, Ceva, Bimeda, Inc., Vivaldis, VetriMax Veterinary Products, Vetoquinol, and Royal Canin North America. 
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global canine atopic dermatitis treatment drugs market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global canine atopic dermatitis treatment drugs market.

Detailed Segmentation-

  • Drug Class:
    • Janus Kinase Inhibitors
    • Antihistamines
    • Monoclonal Antibodies
    • Antibiotics
    • Allergic Immunotherapy/Desensitization Therapy
    • Others
  • Route of Administration:
    • Injectable
    • Oral
    • Topical
  • Dosage Form:
    • Tablets
    • Creams
    • Spray
    • Others
  • Distribution Channel:
    • Online
    • Offline
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Bioiberica S.A.U
    • Dechra Pharmaceuticals PLC
    • Elanco
    • NIPPON ZENYAKU KOGYO CO., LTD
    • Vimian
    • TORAY INDUSTRIES, INC.
    • Zoetis
    • Virbac
    • Ceva
    • Bimeda, Inc.
    • Vivaldis
    • VetriMax Veterinary Products
    • Vetoquinol
    • Royal Canin North America

Detailed Segmentation-

  • Drug Class:
    • Janus Kinase Inhibitors
    • Antihistamines
    • Monoclonal Antibodies
    • Antibiotics
    • Allergic Immunotherapy/Desensitization Therapy
    • Others
  • Route of Administration:
    • Injectable
    • Oral
    • Topical
  • Dosage Form:
    • Tablets
    • Creams
    • Spray
    • Others
  • Distribution Channel:
    • Online
    • Offline
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo